ClinicalTrials.gg
Active, not recruitingNCT01114269Updated Nov 13, 2026

PRE-DETERMINE Cohort Study

An observational study in Coronary Artery Disease, Left Ventricular Dysfunction and Sudden Cardiac Death, sponsored by Brigham and Women's Hospital. Active, not recruiting at 90 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Brigham and Women's Hospital · Observational

How we know

Updated Nov 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,764
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Coronary Artery Disease by Brigham and Women's Hospital — 2 open to participants now, 3 under way, none of them phase 3. Coronary Artery Disease · Brigham and Women's Hospital.

Started
2007
with 2 others
Observational
5 of 18
1 open now
Registered
9th of 18
by date

Among the 18 studies in Coronary Artery Disease by Brigham and Women's Hospital, this one is one of 3 that started in 2007, is one of 5 observational ones, and was the 9th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

2 of the 18 studies in Coronary Artery Disease by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Coronary Artery Disease by Brigham and Women's Hospital, or all of them as a file.
02

Study summary

This is a prospective, multi-center cohort study of patients with a history of coronary artery disease (CAD) and documentation of either a prior myocardial infarction (MI) or mild to moderate left ventricular dysfunction (LVEF 35-50%). The primary objective of this study is to determine whether biologic markers and ECGs can be utilized to advance SCD risk prediction in patients with CHD and LVEF>30-35%. The overarching goal of the study is to identify a series of markers that alone or in combination specifically predict risk of arrhythmic death as compared to other causes of mortality among this at risk population of coronary heart disease (CHD) patients with preserved left ventricular ejection fraction (LVEF> 30-35%). If biologic or ECG markers are identified that can specifically predict risk of ventricular arrhythmias, then these markers may serve as relatively inexpensive methods to identify those at risk. The public health impact of identifying markers could be quite substantial, leading to more efficient utilization of ICDs and advances in our understanding of mechanisms underlying SCD.

Read the detailed description

The PRE-DETERMINE Study is a prospective, multi-center study of patients with a history of coronary artery disease (CAD) and documentation of either a prior myocardial infarction (MI) or mild to moderate left ventricular dysfunction (LVEF 35-50%). Patients were enrolled at 135 sites where information on baseline demographics, clinical characteristics, pertinent past medical history, lifestyle habits, cardiac test results, and medications were collected via electronic data capture. Electrocardiograms along with a blood sample was also collected at baseline, sent to central laboratories, and stored for future analyses. Contrast-enhanced magnetic resonance imaging (CE-MRI) scans were collected on a subset of patients and analyzed. Enrollment closed in November 2013 and patients are now being followed centrally by the Clinical Coordinating Center via mail/phone to document interim non-fatal arrhythmic events and cause-specific mortality. Questionnaires that inquire about intervening ICD implantations, ICD therapies, cardiac arrest, and other pertinent cardiovascular endpoints are mailed to participants every six months, and follow-up telephone calls are made to non-responders. Study endpoints are being confirmed through review of medical records, interviews with next-of-kin, and autopsy reports, if available.

03

Conditions studied

  • Coronary Artery Disease
  • Left Ventricular Dysfunction
  • Sudden Cardiac Death

Keywords

  • Coronary Artery Disease
  • Sudden Cardiac Death
  • Myocardial Infarction
  • Percutaneous Coronary Intervention
  • Implantable Cardiac Defibrillator
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Participants have been recruited throughout multicenter sites participating in the PRE-DETERMINE Cohort Study. Patients with a history of coronary artery disease and documentation of either a prior myocardial infarction (MI) or mild to moderate left ventricular dysfunction (LVEF 35-50%) have been enrolled. The clinical study staff at each site, which was either a research nurse, fellow, or physician approached eligible patients to discuss their potential participation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Evidence of Coronary Artery Disease (CAD) a or documented prior Myocardial Infarction.
  2. >35% by any current standard evaluation technique (e.g.,) echocardiogram, MUGA, angiography). 2.1. Patients who have an LVEF between 30-35% and Class I heart failure who do not have history of ventricular tachyarrhythmias,or inducible ventricular tachycardia during electrophysiological (EP) testing can be enrolled.
  3. If documented prior MI is not present, evidence of mild-moderate systolic Left Ventricular Dysfunction with an EF >35- ≤50% as measured by any current standard screening technique (e.g.,echocardiogram, MUGA, angiography) must be present.
  4. Patients aged 18 years or above

    1. CAD will be defined as evidence of one of the following two (2) criteria:

      • Significant stenosis of a major epicardial vessel (>50% proximal or 70% distal) by coronary angiography
      • Prior revascularization (percutaneous coronary intervention or coronary artery bypass surgery)
    2. MI can be documented in the following ways:

      • From the MI hospitalization: Detection of a rise and fall of cardiac biomarkers > 99th percentile of lab (e.g., CPK elevation or Troponin at least > two times the ) together with myocardial ischemia with at least one of the following:

        • Symptoms of Ischemia
        • changes indicative of new ischemia (new ST-T changes or new LBBB)
        • Development of pathological Q waves
        • Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality
      • If no report from the MI hospitalization is available, prior MI can be met by either of the following:

        • Development of pathological Q waves
        • Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischaemic cause

Exclusion criteria

Exclusion Criteria:

  1. History of cardiac arrest or spontaneous or inducible sustained VT (15 beats or more at a rate of 120 BPM or greater - the occurrence of cardiac arrest or spontaneous VT in the setting of an acute MI is not considered an exclusion).
  2. Unexplained syncope
  3. Current or planned implantable cardiac defibrillator (ICD)
  4. Any condition other than cardiac disease that, in the investigator's judgment, would seriously limit (poor survival)
  5. cancer
  6. Marked valvular heart disease requiring surgical intervention
  7. Current or planned cardiac, renal or liver transplant
  8. Current alcohol or drug abuse
  9. Unwilling or unable to provide
  10. \<35% with Class II-IV CHF or LVEF \<30%
  11. Participation in a clinical trial where the active treatment arm is testing an agent and/or intervention with known antiarrhythmic properties
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,764 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Sudden and/or arrhythmic cardiac death or resuscitated ventricular fibrillation.

    A definite sudden cardiac death (SCD) is defined as a death or fatal cardiac arrest occurring within 1 hour of symptom onset or the presence of autopsy consistent with SCD (e.g. acute coronary thrombosis). Probable SCD is defined as an unwitnessed death or death during sleep where the participant was observed to be symptom-free within the preceding 24 hours. Arrhythmic death is defined as the abrupt spontaneous collapse of circulation without antecedent circulatory or neurologic impairment. Deaths classified as non-arrhythmic are not included in the primary endpoint regardless of timing. Resuscitated ventricular fibrillation is defined as out-of-hospital cardiac arrests with documented VF and/or use of external electrical defibrillation for resuscitation.

    Time frame: Median follow-up estimated to be 10.7 years

Secondary outcomes

  1. ICD Shock

    ICD therapies for ventricular arrhythmias over 200 BPMs will be added to the endpoint.

    Time frame: Median follow-up estimated to be 10.7 years

  2. ICD Implantation

    Time frame: Median follow-up estimated to be 10.7 years

  3. Total Cardiac Mortality

    Time frame: Median follow-up estimated to be 10.7 years

  4. Total Mortality

    Time frame: Median follow-up estimated to be 10.7 years

  5. Non-Sudden or Arrhythmic Causes of Mortality

    Competing causes of mortality in competing risk analyses.

    Time frame: Median follow-up estimated to be 10.7 years

07

Study locations

90 sites
  • Alaska Heart Institute
    Anchorage, Alaska 99508, United States
  • Phoenix Heart, PLLC
    Glendale, Arizona 85306, United States
  • Cardiovascular Consultants
    Phoenix, Arizona 85032, United States
  • Beaver Medical Group/Clinical Care Research
    Banning, California 92220, United States
  • Memorial Health System
    Colorado Springs, Colorado 80909, United States
  • Colorado Heart and Vascular
    Denver, Colorado 80204, United States
  • Bay Area Cardiology Associates, P.A.
    Brandon, Florida 33511, United States
  • University of Florida - Gainsville
    Gainesville, Florida 32610, United States
  • Reliable Clinical Research
    Miami, Florida 33135, United States
  • Mount Sinai Medical Center
    Miami Beach, Florida 33140, United States
  • Florida Hospital
    Orlando, Florida 32804, United States
  • Orlando Regional Medical Center
    Orlando, Florida 32806, United States
  • Palm Beach Gardens Research Center
    Palm Beach Gardens, Florida 33410, United States
  • Velella Research
    Sarasota, Florida 34233, United States
  • Tallahassee Research Institute, Inc.
    Tallahassee, Florida 32308, United States
  • Cardiology Associates of Palm Beach - West Palm Beach
    West Palm Beach, Florida 33401, United States
  • Georgia Heart Specialist
    Covington, Georgia 30014, United States
  • Northeast Georgia Heart Center, P.C.
    Gainesville, Georgia 30501, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Advocate Medical Group
    Chicago, Illinois 60643, United States
  • Advocate Medical Group - Heart and Vascular of IL
    Chicago, Illinois 60657, United States
  • Consultants in Cardiovascular Medicine
    Melrose Park, Illinois 60160, United States
  • Community Heart and Vascular
    Anderson, Indiana 46011, United States
  • Iowa Heart Center
    West Des Moines, Iowa 50266, United States
  • The University of Kansas
    Kansas City, Kansas 66160, United States
  • Baptist Health Lexington
    Lexington, Kentucky 40503, United States
  • Leonard J. Chabert Medical Center
    Houma, Louisiana 70363, United States
  • Maine Research Associates
    Auburn, Maine 04210, United States
  • Maine Research Associates - Lewiston
    Lewiston, Maine 04240, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Primary Care Cardiology Research
    Ayer, Massachusetts 01432, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • NECCR Internal Medicine and Cardiology Associates, LLC
    Fall River, Massachusetts 02720, United States
  • Hawthorn Medical Associates
    North Dartmouth, Massachusetts 02747, United States
  • Baystate Cardiology
    Springfield, Massachusetts 01199, United States
  • University of Michigan Medical Center
    Ann Arbor, Michigan 48109, United States
  • Oakwood Hospital & Medical Center
    Dearborn, Michigan 48124, United States
  • McLaren Medical Center - Macomb
    Mount Clemens, Michigan 48043, United States
  • Michigan Heart
    Ypsilanti, Michigan 48197, United States
  • Minneapolis VA Medical Center
    Minneapolis, Minnesota 55417, United States
  • University of Missouri Health Care
    Columbia, Missouri 65201, United States
  • Glacier View Cardiology
    Kalispell, Montana 59901, United States
  • The Cardiac Center of Creighton University
    Omaha, Nebraska 68131, United States
  • Advanced Heartcare, LLC
    Bridgewater, New Jersey 08807, United States
  • St. Joseph Regional Medical Center
    Paterson, New Jersey 07503, United States
  • New Mexico VA Healthcare Systems
    Albuquerque, New Mexico 87108, United States
  • Albany Associates Cardiology
    Albany, New York 12205, United States
  • Maimonides Medical Center
    Brooklyn, New York 11219, United States
  • Buffalo General Hospital/Kaleida Health
    Buffalo, New York 14203, United States
  • Jamaica Hospital Medical Center
    Jamaica, New York 11418, United States
  • Mid-Valley Cardiology
    Kingston, New York 12401, United States
  • Winthrop-University Hospital
    Mineola, New York 11501, United States
  • Gotham Cardiovascular
    New York, New York 10001, United States
  • Columbia University Health Center
    New York, New York 10032, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11794, United States
  • St. Elizabeth Medical Center - Hotvedt
    Utica, New York 13501, United States
  • Asheville Cardiology Associates
    Asheville, North Carolina 28801, United States
  • Eastern Carolina Cardiovascular
    Elizabeth City, North Carolina 27909, United States
  • Northstate Clinical Research
    Lenoir, North Carolina 28645, United States
  • Pinehurst Medical Clinic, Inc.
    Pinehurst, North Carolina 28374, United States
  • Sanford Cardiology
    Sanford, North Carolina 27330, United States
  • Wake Forest
    Winston-Salem, North Carolina 27157, United States
  • Northeast Ohio Cardiovascular Specialists
    Akron, Ohio 44304, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • MetroHealth Medical Center
    Cleveland, Ohio 44109, United States
  • North Ohio Research, Ltd.
    Elyria, Ohio 44035, United States
  • Mercy Medical Associates
    Fairfield, Ohio 45014, United States
  • Northwest Ohio Cardiology Consultants/The Toledo Hospital
    Toledo, Ohio 43615, United States
  • Oklahoma City VA Medical Center Veterans Research and Education Foundation
    Oklahoma City, Oklahoma 73104, United States
  • Oklahoma Foundation for Cardiovascular Research
    Oklahoma City, Oklahoma 73120, United States
  • Abington Memorial Hospital
    Abington, Pennsylvania 19001, United States
  • St. Luke's Bethlehem
    Bethlehem, Pennsylvania 18018, United States
  • Doylestown Cardiology Associates
    Doylestown, Pennsylvania 18901, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • AnMed Health
    Anderson, South Carolina 29621, United States
  • VA Medical Center - Charleston
    Charleston, South Carolina 29425, United States
  • Carolina Cardiology Associates
    Rock Hill, South Carolina 29732, United States
  • Black Hills Cardiovascular Research
    Rapid City, South Dakota 57701, United States
  • Cardiovasular Research of Knoxville
    Knoxville, Tennessee 37917, United States
  • Memphis VA Medical Center
    Memphis, Tennessee 38104, United States
  • St. Luke's Episcopal Hospital
    Houston, Texas 77030, United States
  • Non-Invasive Cardiovascular PA
    Houston, Texas 77074, United States
  • Providence Health Center
    Waco, Texas 76712, United States
  • Intermountain Medical Center
    Murray, Utah 84157, United States
  • Cardiovascular Associates Virginia Beach
    Virginia Beach, Virginia 23454, United States
  • University of Alberta
    Edmonton, Alberta T6G 2B7, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • Mississauga Clinical Research Centre
    Mississauga, Ontario L5B 2P7, Canada
  • Transcatheter Medical, Inc. Centro Cardiovascular de Caguas y del Caribe
    Rio Piedras, 00924, Puerto Rico
08

References and documents

Publications

  • Chatterjee NA, Moorthy MV, Pester J, Schaecter A, Panicker GK, Narula D, Lee DC, Goldberger JJ, Kadish A, Cook NR, Albert CM; PRE-DETERMINE Study Group. Sudden Death in Patients With Coronary Heart Disease Without Severe Systolic Dysfunction. JAMA Cardiol. 2018 Jul 1;3(7):591-600. doi: 10.1001/jamacardio.2018.1049. PubMed 29801082 ↗
  • Lee DC, Albert CM, Narula D, Kadish AH, Panicker GK, Wu E, Schaechter A, Pester J, Chatterjee NA, Cook NR, Goldberger JJ. Estimating Myocardial Infarction Size With a Simple Electrocardiographic Marker Score. J Am Heart Assoc. 2020 Feb 4;9(3):e014205. doi: 10.1161/JAHA.119.014205. Epub 2020 Jan 24. PubMed 31973600 ↗
  • Chatterjee NA, Tikkanen JT, Panicker GK, Narula D, Lee DC, Kentta T, Junttila JM, Cook NR, Kadish A, Goldberger JJ, Huikuri HV, Albert CM; PREDETERMINE Investigators. Simple electrocardiographic measures improve sudden arrhythmic death prediction in coronary disease. Eur Heart J. 2020 Jun 1;41(21):1988-1999. doi: 10.1093/eurheartj/ehaa177. PubMed 32259257 ↗
  • Silverman MG, Yeri A, Moorthy MV, Camacho Garcia F, Chatterjee NA, Glinge CSA, Tfelt-Hansen J, Salvador AM, Pico AR, Shah R, Albert CM, Das S. Circulating miRNAs and Risk of Sudden Death in Patients With Coronary Heart Disease. JACC Clin Electrophysiol. 2020 Jan;6(1):70-79. doi: 10.1016/j.jacep.2019.08.011. Epub 2019 Oct 30. PubMed 31971908 ↗
  • Sandhu RK, Dron JS, Liu Y, Moorthy MV, Chatterjee NA, Ellinor PT, Chasman DI, Cook NR, Khera AV, Albert CM. Polygenic Risk Score Predicts Sudden Death in Patients With Coronary Disease and Preserved Systolic Function. J Am Coll Cardiol. 2022 Aug 30;80(9):873-883. doi: 10.1016/j.jacc.2022.05.049. PubMed 36007985 ↗
  • Peek N, Hindricks G, Akbarov A, Tijssen JGP, Jenkins DA, Kapacee Z, Parkes LM, van der Geest RJ, Longato E, Sprague D, Taleb Y, Ong M, Miller CA, Shamloo AS, Albert C, Barthel P, Boveda S, Braunschweig F, Johansen JB, Cook N, de Chillou C, Elders P, Faxen J, Friede T, Fusini L, Gale CP, Jarkovsky J, Jouven X, Junttila J, Kautzner J, Kiviniemi A, Kutyifa V, Leclercq C, Lee DC, Leigh J, Lenarczyk R, Leyva F, Maeng M, Manca A, Marijon E, Marschall U, Merino JL, Mont L, Nielsen JC, Olsen T, Pester J, Pontone G, Roca I, Schmidt G, Schwartz PJ, Sticherling C, Suleiman M, Taborsky M, Tan HL, Tfelt-Hansen J, Thiele H, Tomaselli GF, Verstraelen T, Vinayagamoorthy M, Olesen KKW, Wilde A, Willems R, Wu KC, Zabel M, Martin GP, Dagres N. Sudden cardiac death after myocardial infarction: individual participant data from pooled cohorts. Eur Heart J. 2024 Nov 14;45(43):4616-4626. doi: 10.1093/eurheartj/ehae326. PubMed 39378245 ↗
  • Panicker GK, Narula DD, Albert CM, Lee DC, Kothari S, Goldberger JJ, Cook N, Schaechter A, Kim E, Moorthy MV, Pester J, Chatterjee NA, Kadish AH, Karnad DR. Validation of electrocardiographic criteria for identifying left ventricular dysfunction in patients with previous myocardial infarction. Ann Noninvasive Electrocardiol. 2021 Mar;26(2):e12812. doi: 10.1111/anec.12812. Epub 2020 Oct 30. PubMed 33124739 ↗
  • Venkateswaran RV, Moorthy MV, Chatterjee NA, Pester J, Kadish AH, Lee DC, Cook NR, Albert CM. Diabetes and Risk of Sudden Death in Coronary Artery Disease Patients Without Severe Systolic Dysfunction. JACC Clin Electrophysiol. 2021 Dec;7(12):1604-1614. doi: 10.1016/j.jacep.2021.05.014. Epub 2021 Jul 28. PubMed 34332876 ↗
  • Adabag S, Patton KK, Buxton AE, Rector TS, Ensrud KE, Vakil K, Levy WC, Poole JE. Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial. JAMA Cardiol. 2017 Jul 1;2(7):767-774. doi: 10.1001/jamacardio.2017.1413. PubMed 28724134 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2007 (actual). Primary completion is estimated for Nov 2027, 244 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 244 months is above that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Nov 2026 → Nov 2027 and completion Nov 2026 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2010
First posted
May 3, 2010
StartActual
Jul 2007
Primary completionEst.
Nov 2027was Nov 2026
CompletionEst.
Nov 2027was Nov 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2026→Nov 2027
Nov 13, 2026
Study completion
Nov 2026→Nov 2027
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Primary completion Nov 2026→Nov 2027
    Study completion Nov 2026→Nov 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01114269
Responsible party
Christine M. Albert, MD, MPH (Principal Investigator, Brigham and Women's Hospital) — Principal investigator
First posted
May 3, 2010
Start date
Jul 2007
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Christine M Albert, M.D., M.P.H.
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion